In patients with NSCLC treated with durvalumab, improved survival was observed especially in CD8+/PD-L1+ tumors (24.3 months) compared with CD8+ (17.8 months) or PD-L1+ (17.1 months) (Shien et al., 2016). This evidence concerns the gene CD274 and non-small cell lung carcinoma.